<DOC>
	<DOC>NCT01196091</DOC>
	<brief_summary>The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in addition to standard of care therapy in patients with active SLE.</brief_summary>
	<brief_title>A Study of LY2127399 in Patients With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria Have positive antinuclear antibodies (ANA) Agree not to become pregnant throughout the course of the trial Have the appropriate Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENASLEDAI)score at screening Have active severe Lupus kidney disease Have active Central Nervous System or peripheral neurologic disease Have received intravenous immunoglobulin (IVIg) within 180 days of randomization Have active or recent infection within 30 days of screening Have had a serious infection within 90 days of randomization Have evidence or test positive for Hepatitis B Have Hepatitis C Are human immunodeficiency virus (HIV) positive Have evidence of active or latent tuberculosis (TB) Presence of significant laboratory abnormalities at screening Have had a malignancy in the past 5 years, except for cervical carcinoma insitu or basal cell or squamous epithelial skin cell that were completely resected with no reoccurrence in the 3 yrs prior to randomization Have received greater than 40 mgs of prednisone or equivalent in the past 30 days Have changed your dose of antimalarial drug in the past 30 days Have changed your dose of immunosuppressive drug in the past 90 days Have previously received rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
	<keyword>Systemic Lupus Erythematosis</keyword>
	<keyword>autoimmune disease</keyword>
	<keyword>LY2127399</keyword>
	<keyword>Immune system disease</keyword>
</DOC>